Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288366 · ClinicalTrials.gov registry record · NA
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT00288366 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 49 participants.
The verdict
NCT00288366, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs). Patients will be switched from their current antipsychotic medication to aripiprazole (Abilify) or ziprasidone (Geodon) (unless clinically contraindicated) for comparison with metabolic levels during treatment with the former medication. The metabolic syndrome is an empirical concept based on extensive evidence that a constellation of 5 metabolic abnormalities, e.g. increased cholesterol, hypertension, low HDL, taken together, predict marked increases in the risk of CVD, stroke and some types of cancer.
Interventions
- DRUG ziprasidone vs. aripiprazole
- DRUG aripiprazole vs. ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288366
The ClinicalTrials.gov registry entry for NCT00288366 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ziprasidone vs. aripiprazole is the first listed.
NCT00288366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288366 about?
NCT00288366 is a clinical study titled "Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome". The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs). Patients will be switched from their current antipsychotic medication to...
What is the current status of trial NCT00288366?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2006-01. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00288366?
The interventions under investigation include: ziprasidone vs. aripiprazole (DRUG), aripiprazole vs. ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00288366?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.